LL-37 analogs and computational design strategies emerge as key tools against LPS-mediated resistance in Gram-negative pathogens
Background
Antimicrobial resistance (AMR) in Gram-negative bacteria is a critical global health issue, largely driven by lipopolysaccharide (LPS) in their outer membrane. LPS acts as a robust permeability barrier, hindering antibiotic entry, and its adaptive modifications enhance bacterial resistance. Conventional antibiotics often fail against LPS-mediated resistance. The human cathelicidin LL-37, a potent endogenous antimicrobial peptide (AMP), shows promise due to its LPS affinity and membrane-disrupting capabilities. However, its therapeutic application is hampered by stability, toxicity, and cost, necessitating the development of improved analogs.
Study Design
This comprehensive review systematically analyzed the molecular diversity and structure-activity relationships (SAR) of LL-37 analogs. Researchers focused on key parameters including charge distribution, helicity, hydrophobicity, selectivity, and LPS-binding efficiency. The review specifically highlighted analogs engineered to overcome LPS-mediated resistance in multidrug-resistant Gram-negative pathogens. Furthermore, it detailed advancements in computational techniques like molecular docking, MD simulations, and AI-assisted design that aid peptide optimization, noting a gap where five clinically relevant analogs lack computational study.
Results
The review extensively characterized the molecular diversity of LL-37 analogs, elucidating their structure-activity relationships (SAR) across various design strategies including truncation, residue substitution, and cyclization. It emphasized how optimizing parameters like charge distribution, helicity, hydrophobicity, and LPS-binding efficiency is crucial for enhancing antibacterial efficacy while minimizing host toxicity. The analysis highlighted numerous analogs specifically engineered to overcome LPS-mediated resistance in multidrug-resistant Gram-negative pathogens.
A significant finding was the identification of a computational gap: five of nine clinically relevant LL-37 analogs have not yet been subjected to computational analysis, suggesting a missed opportunity for accelerated optimization. The review also showcased the increasing role of advanced computational techniques, such as
molecular docking,molecular dynamics (MD) simulations, andartificial intelligence (AI)-assisted design, in identifying critical interaction hotspots and expediting the development of novel AMPs.
Key Findings
- LL-37 analogs are being engineered to overcome LPS-mediated resistance in Gram-negative pathogens.
- Structure-activity relationships (SAR) involving charge, helicity, hydrophobicity, and LPS-binding are key to analog design.
- Computational techniques like molecular docking and AI are accelerating antimicrobial peptide (AMP) optimization.
- Five of nine clinically relevant LL-37 analogs lack computational study, representing a significant research gap.
Why It Matters
This review underscores the critical need for novel antimicrobial strategies against Gram-negative pathogens and positions LL-37 analogs as a promising solution. For peptide users and researchers, this work highlights the potential for engineered antimicrobial peptides (AMPs) to overcome the limitations of native LL-37, offering improved stability, reduced toxicity, and enhanced efficacy against drug-resistant bacteria. The emphasis on computational design strategies suggests a future where AMP development is significantly accelerated, potentially leading to faster translation from lab to clinic. Identifying the gap in computational studies for existing clinically relevant analogs points to immediate research opportunities, potentially unlocking optimized protocols or novel applications for these compounds. This could pave the way for a new generation of targeted AMP therapies, addressing a major unmet medical need.
ll-37
antimicrobial-peptide
gram-negative-bacteria
antimicrobial-resistance
lps
computational-design